ATE319844T1 - Verfahren zur herstellung von viren - Google Patents

Verfahren zur herstellung von viren

Info

Publication number
ATE319844T1
ATE319844T1 AT99921681T AT99921681T ATE319844T1 AT E319844 T1 ATE319844 T1 AT E319844T1 AT 99921681 T AT99921681 T AT 99921681T AT 99921681 T AT99921681 T AT 99921681T AT E319844 T1 ATE319844 T1 AT E319844T1
Authority
AT
Austria
Prior art keywords
methods
producer cells
viruses
further provides
exogenous
Prior art date
Application number
AT99921681T
Other languages
English (en)
Inventor
Daniel D Giroux
Ann M Goudreau
Muralidhara Ramachandra
Paul W Shabram
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22111581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE319844(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of ATE319844T1 publication Critical patent/ATE319844T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT99921681T 1998-05-04 1999-05-04 Verfahren zur herstellung von viren ATE319844T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/073,076 US5994134A (en) 1998-05-04 1998-05-04 Viral production process

Publications (1)

Publication Number Publication Date
ATE319844T1 true ATE319844T1 (de) 2006-03-15

Family

ID=22111581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99921681T ATE319844T1 (de) 1998-05-04 1999-05-04 Verfahren zur herstellung von viren

Country Status (9)

Country Link
US (1) US5994134A (de)
EP (2) EP1078095B2 (de)
JP (3) JP2002513583A (de)
AT (1) ATE319844T1 (de)
AU (1) AU3882399A (de)
CA (1) CA2328084C (de)
DE (1) DE69930250T3 (de)
ES (1) ES2257861T5 (de)
WO (1) WO1999057297A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291226B1 (en) * 1999-02-25 2001-09-18 National Research Council Of Canada Adenovirus mutants with deleted protease gene
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
JP2005521417A (ja) * 2002-03-29 2005-07-21 メルク　エンド　カムパニー　インコーポレーテッド アデノウイルスの大規模産生方法及びアデノウイルス種子ストック
JP2004149002A (ja) * 2002-10-31 2004-05-27 Yamaha Motor Co Ltd スノーモービルのリヤサスペンション
JP2004196222A (ja) * 2002-12-20 2004-07-15 Yamaha Motor Co Ltd 雪上車の懸架装置
US7318494B2 (en) * 2002-12-20 2008-01-15 Yamaha Hatsudoki Kabushiki Kaisha Snow vehicle suspension system
JP2004217195A (ja) * 2002-12-26 2004-08-05 Yamaha Motor Co Ltd 雪上車の懸架装置
AU2005214090B2 (en) * 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
DE102004049290A1 (de) * 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
CN101208425B (zh) * 2004-12-13 2011-01-26 坎吉有限公司 产生复制缺陷型腺病毒的细胞系
US8574595B2 (en) * 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
CA2633087C (en) * 2005-12-12 2014-12-02 Canji, Inc. Adenoviral expression vectors
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2013063383A2 (en) 2011-10-27 2013-05-02 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
JP5644885B2 (ja) 2013-03-19 2014-12-24 大日本印刷株式会社 印画物の製造方法
EP2986306A4 (de) 2013-04-18 2016-12-07 Armo Biosciences Inc Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
CA3231933A1 (en) * 2021-09-30 2023-04-06 Barbara Leuchs Method for further upscaling the large-scale production of the oncolytic h-1 protoparvovirus (h-1pv) using a carrier-based production process combined with an optimized cell culture medium
WO2023208212A1 (zh) * 2022-04-29 2023-11-02 北京华龛生物科技有限公司 基于三维多孔微载体的病毒载体生产方法
WO2024206928A1 (en) 2023-03-30 2024-10-03 Pharma Cinq, Llc VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219752A (en) * 1988-05-25 1993-06-15 Teijin, Limited Process for continuously culturing adherent animal cells
US5270189A (en) * 1990-07-03 1993-12-14 Martin Marietta Energy Systems, Inc. Biparticle fluidized bed reactor
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
CA2216871A1 (en) † 1995-04-20 1996-10-24 Chiron Corporation High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
EP0821740A1 (de) † 1995-04-20 1998-02-04 Chiron Corporation Hocheffiziente, ex-vivo, transduktion von hämatopoietischen stammzellen mit rekombinante xenotrope retroviren
AU1333797A (en) * 1995-12-15 1997-07-03 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency

Also Published As

Publication number Publication date
DE69930250T3 (de) 2017-01-26
US5994134A (en) 1999-11-30
EP1657309A1 (de) 2006-05-17
CA2328084A1 (en) 1999-11-11
JP2013165736A (ja) 2013-08-29
EP1657309A8 (de) 2010-06-02
JP2009297044A (ja) 2009-12-24
ES2257861T5 (es) 2017-03-23
EP1078095B2 (de) 2016-09-07
EP1078095A1 (de) 2001-02-28
CA2328084C (en) 2008-09-30
AU3882399A (en) 1999-11-23
JP2002513583A (ja) 2002-05-14
DE69930250T2 (de) 2006-12-07
DE69930250D1 (de) 2006-05-04
EP1078095B1 (de) 2006-03-08
WO1999057297A1 (en) 1999-11-11
ES2257861T3 (es) 2006-08-01

Similar Documents

Publication Publication Date Title
ATE319844T1 (de) Verfahren zur herstellung von viren
Hsu et al. Investigation of optimal transduction conditions for baculovirus‐mediated gene delivery into mammalian cells
IL149788A (en) Production of vaccines
RU2004121178A (ru) Способ крупномасштабного производства вирусного антигена
Capasso et al. The culture of chick embryo chondrocytes and the control of their differentiated functions in vitro: I. Characterization of the chondrocyte-specific phenotypes
Roner et al. Reovirus RNA is infectious
GR3034722T3 (en) ENHANCED PRODUCTION OF TAXOL AND TAXANES BY CELL CULTURES OF -i(TAXUS) SPECIES.
KR20120033334A (ko) 백신 제조를 위한 고역가 폴리오바이러스의 제조
JP2005532779A5 (de)
CN1121959A (zh) 重组的感染性不分节段的负链rna病毒
DE60141014D1 (de) Verfharen zur herstellung von herpes-simplex-virus-amplikons, die resultierenden amplikons und ihre verwendung
Genty et al. Is cytoskeleton involved in vesicular stomatitis virus reproduction?
Schlesinger et al. An in-frame insertion into the Sindbis virus 6K gene leads to defective proteolytic processing of the virus glycoproteins, a trans-dominant negative inhibition of normal virus formation, and interference in virus shut off of host-cell protein synthesis
CN112094814B (zh) 一种通过灌流培养工艺制备腺病毒载体疫苗的方法
Youngner et al. Generation and amplification of temperature-sensitive mutants during serial undiluted passages of vesicular stomatitis virus
ATE424464T1 (de) Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren
WO2020219897A1 (en) Methods for production of recombinant adeno-associated viruses
KR20140036144A (ko) 고수율 현탁세포주, 시스템 및 그 제조방법
CN101255407B (zh) 永生化大鼠骨髓基质细胞系及其制备方法
CN107254437A (zh) 一种人工诱导多能干细胞分化为红细胞的方法
US20230257719A1 (en) Production of High Titer Recombinant Vesicular Stomatitis Virus in Suspension Cell Culture
Simizu et al. A variant of western equine encephalitis virus with nonglycosylated E3 protein
Eaton Sindbis virus variants from a persistently infected mosquito cell culture contain an altered E2 glycoprotein
Cahn et al. CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin
US4992374A (en) Mutant vaccinia virus and process for production thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties